Sagimet Biosciences (SGMT) Common Equity (2022 - 2026)

Sagimet Biosciences' Common Equity history runs 5 years deep, the most recent figure standing at $102.5 million for Q1 2026.

• On a quarterly basis, Common Equity fell 26.28% year-over-year to $102.5 million in Q1 2026; TTM through Mar 2026 was $102.5 million, a 26.28% decrease from a year earlier, with the FY2025 full-year figure at $111.4 million, down 28.51% from the prior year.
• Common Equity fell to $102.5 million in Q1 2026 per SGMT's latest filing, from $111.4 million in the prior quarter.
• Across five years, Common Equity topped out at $190.0 million in Q1 2024 and bottomed at -$198.4 million in Q2 2023.
• The 5-year median for Common Equity is $106.9 million (2025), against an average of $34.9 million.
• Across the five-year window, Common Equity surged 198.61% in 2024 and tumbled 30.13% in 2025, its largest moves.
• Year by year, Common Equity stood at -$187.0 million in 2022, then surged by 148.71% to $91.1 million in 2023, then soared by 71.09% to $155.8 million in 2024, then retreated by 28.51% to $111.4 million in 2025, then retreated by 8.01% to $102.5 million in 2026.
• Per Business Quant, the three latest SGMT Common Equity figures stand at $102.5 million (Q1 2026), $111.4 million (Q4 2025), and $119.3 million (Q3 2025).